Caribou Biosciences Management
Management criteria checks 2/4
Caribou Biosciences' CEO is Rachel Haurwitz, appointed in Oct 2011, has a tenure of 13.25 years. total yearly compensation is $3.12M, comprised of 20% salary and 80% bonuses, including company stock and options. directly owns 0.044% of the company’s shares, worth $68.80K. The average tenure of the management team and the board of directors is 2.9 years and 3.7 years respectively.
Key information
Rachel Haurwitz
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 20.0% |
| CEO tenure | 13.3yrs |
| CEO ownership | 0.04% |
| Management average tenure | 2.9yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Caribou Biosciences: CB-010 And Other CAR-Ts Pressing Forward Despite Initial Data
Jan 02Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely
Dec 31
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry
Nov 05Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
Sep 30Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation
Sep 06Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too
Jul 26Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential
Jul 03Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding
Jun 05Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Apr 18More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%
Apr 17Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up
Feb 15Caribou Biosciences: Under The Radar With Catalysts Approaching
Feb 01Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans
Jan 10Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues
Nov 18Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Feb 24Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability
Oct 12Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth
Sep 16Caribou Biosciences: Potential To Change CAR-T Landscape
Aug 01Crispred CAR-T Cells In The Clinic
May 19Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 13Caribou Biosciences: Selling Close To Cash Balance
Apr 26We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate
Oct 26Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold
Oct 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$148m |
| Jun 30 2024 | n/a | n/a | -US$123m |
| Mar 31 2024 | n/a | n/a | -US$115m |
| Dec 31 2023 | US$3m | US$623k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$95m |
| Jun 30 2023 | n/a | n/a | -US$111m |
| Mar 31 2023 | n/a | n/a | -US$108m |
| Dec 31 2022 | US$833k | US$513k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$91m |
| Jun 30 2022 | n/a | n/a | -US$85m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$6m | US$527k | -US$67m |
| Sep 30 2021 | n/a | n/a | -US$63m |
| Jun 30 2021 | n/a | n/a | -US$50m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$664k | US$450k | -US$34m |
| Dec 31 2019 | US$540k | US$425k | -US$23m |
Compensation vs Market: Rachel's total compensation ($USD3.12M) is above average for companies of similar size in the US market ($USD1.41M).
Compensation vs Earnings: Rachel's compensation has increased whilst the company is unprofitable.
CEO
Rachel Haurwitz (38 yo)
13.3yrs
Tenure
US$3,116,547
Compensation
Dr. Rachel E. Haurwitz, Ph D., has been the President and Chief Executive Officer at Caribou Biosciences, Inc. since October 2011. She served as independent Director at Seer, Inc. since December 21, 2023 u...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.3yrs | US$3.12m | 0.044% $ 68.8k | |
| Chief Scientific Officer | 7.6yrs | US$1.22m | 0.39% $ 608.9k | |
| Chief Legal Officer & Corporate Secretary | 9.8yrs | US$1.22m | 0.42% $ 647.7k | |
| Chief Financial Officer | no data | no data | no data | |
| Vice President of Operations & Information Technology | 2.6yrs | no data | no data | |
| Interim Principal Accounting Officer & Controller | less than a year | no data | 0.078% $ 121.2k | |
| Chief Technology Officer | less than a year | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | 3.2yrs | no data | no data | |
| Chief People Officer | 1.3yrs | no data | no data | |
| Chief Business Officer | 3.2yrs | US$1.04m | 0% $ 0 |
2.9yrs
Average Tenure
52yo
Average Age
Experienced Management: CRBU's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.3yrs | US$3.12m | 0.044% $ 68.8k | |
| Independent Chairman | 3.8yrs | US$202.74k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.6yrs | US$155.86k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.7yrs | US$136.99k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.3yrs | US$157.20k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$140.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.7yrs
Average Tenure
59yo
Average Age
Experienced Board: CRBU's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 02:26 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Caribou Biosciences, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Geoffrey Meacham | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |